Status:
COMPLETED
High and Low Resource Interventions to Promote HPV Vaccines
Lead Sponsor:
Children's Mercy Hospital Kansas City
Collaborating Sponsors:
University of Kansas Medical Center
Midwest Cancer Alliance
Conditions:
Human Papilloma Virus
Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Human Papillomavirus (HPV) is a significant public health issue affecting nearly 14 million people in the United States. HPV can lead to cervical, oropharyngeal, anal, and penile cancers as well as ge...
Detailed Description
Significance: Human Papillomavirus (HPV) is the most common sexually transmitted infection in the United States with an estimated 14 million new infections each year. While most HPV infections resolve...
Eligibility Criteria
Inclusion
- Parent or legal guardian of a child 11-18 years of age or a pediatric health care provider
- Parent or legal guardian of a child being seen for a well-child visit
- Ability to provide informed consent
Exclusion
- Prior participation in the study
- Unable to read or understand English
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 6 2020
Estimated Enrollment :
225 Patients enrolled
Trial Details
Trial ID
NCT03824093
Start Date
July 1 2018
End Date
May 6 2020
Last Update
January 20 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Mercy Hospital Kansas City
Kansas City, Missouri, United States, 64108